The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 18, 2023

Filed:

Mar. 28, 2019
Applicants:

Merck Sharp & Dohme Llc, Rahway, NJ (US);

Michael D. Altman, Needham, MA (US);

Brandon D. Cash, Stoughton, MA (US);

Jared N. Cumming, Winchester, MA (US);

Duane E. Demong, Hanover, MA (US);

Andrew M. Haidle, Somerville, MA (US);

James P. Jewell, Newton, MA (US);

Matthew A. Larsen, Dedham, MA (US);

Min LU, Brookline, MA (US);

Ryan D. Otte, Natick, MA (US);

Brandon M. Taoka, San Francisco, CA (US);

Benjamin Wesley Trotter, Medfield, MA (US);

Quang T. Truong, Morganville, NJ (US);

Inventors:

Michael D. Altman, Needham, MA (US);

Brandon D. Cash, Stoughton, MA (US);

Jared N. Cumming, Winchester, MA (US);

Duane E. DeMong, Hanover, MA (US);

Andrew M. Haidle, Somerville, MA (US);

James P. Jewell, Newton, MA (US);

Matthew A. Larsen, Dedham, MA (US);

Min Lu, Brookline, MA (US);

Ryan D. Otte, Natick, MA (US);

Brandon M. Taoka, San Francisco, CA (US);

Benjamin Wesley Trotter, Medfield, MA (US);

Quang T. Truong, Morganville, NJ (US);

Assignee:

Merck Sharp & Dohme LLC, Rahway, NJ (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07D 513/04 (2006.01); C07D 495/04 (2006.01); C07D 277/64 (2006.01); A61P 37/04 (2006.01); A61P 35/00 (2006.01);
U.S. Cl.
CPC ...
C07D 513/04 (2013.01); A61P 37/04 (2018.01); C07D 495/04 (2013.01);
Abstract

Compounds of general formula (I), and their pharmaceutically acceptable salts, wherein R, R, R, R, R, R, R, A, X, X, and Xare defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are compositions comprising such compounds, processes for the synthesis of such compounds, and to uses of such compounds, including administration of such compounds to induce immune response, to induce STING-dependent type I interferon production, and/or to treat a cell proliferation disorder, such as cancer.


Find Patent Forward Citations

Loading…